Clinical trial
MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV)…
NCT00121108 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00121108 |
|---|---|
| Title | MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States |
| Official title | A Phase 3 Study of MEDI-524 (Motavizumab), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological, Other |
| Interventions | Motavizumab, Placebo |
| Enrollment | 2,127 |
| Start date | Nov 15, 2004 |
| Primary completion | Dec 27, 2010 |
| Completion | Dec 27, 2010 |
| First posted | Jul 21, 2005 |
| Last update posted | Jan 5, 2022 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: